Truist raised the firm’s price target on Veeva (VEEV) to $268 from $230 and keeps a Hold rating on the shares ahead of the company’s quarterly report on August 27. Given the favorable commentary from Doximity (DOCS) n not seeing any slowdown in its end markets and Iqvia (IQV) from its pharma tech and analytics discretionary spend perspective, the firm believes results for Veeva are likely to come in in-line or better. However, with the shares up roughly 20% since the Q1 report, Truist believes investor expectations are already for a slight “beat and raise,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems and IQVIA Settle Litigation, Announce Partnership
- Iqvia and Veeva announce partnership and resolution of disputes
- Veeva Systems: Strong Client Retention and Product Innovation Drive Buy Rating
- Six of top 20 pharma companies committed to Veeva Vault CRM, says Barclays
- Oppenheimer sees Merck agreement as strong endorsement for Veeva’s Vault CRM